Moldotashev I K, Noruzbaeva A M, Tenenbaum A M
Ter Arkh. 1987;59(4):100-3.
Altogether 52 patients with severe forms of congestive cardiac failure (CCF) developing as a result of rheumatic valvular heart diseases, were examined. The patients were divided into 2 groups: 35 living permanently in the lowlands (LL) and 17 living in the highlands (HL). All the patients received corinfar (nifedipine) as part of multimodality therapy at a single dose of 20 mg/m2 with 8-h intervals for 10 days. The results of the administration of the drug in a single dose or in a course were controlled on clinical observation and by instrumental examination including electro- and echocardiography, tetrapolar chest rheography and indirect measurement of pressure in the pulmonary artery (PPA). PPA direct measurement was performed in 8 patients. At both altitudes corinfar resulted in the improvement of the patients' general status, postexercise recovery reduction, a decrease in PPA and mitral regurgitation volume, and an increase in the efficacy of cardiac pump function. Corinfar did not make any noticeable effect on preload and myocardial contractility. Therefore the drug can be recommended for multimodality therapy of CCF both in the high- and lowlands.
共检查了52例因风湿性瓣膜性心脏病导致严重充血性心力衰竭（CCF）的患者。这些患者被分为两组：35例长期居住在低地（LL），17例居住在高地（HL）。所有患者均接受了可立平（硝苯地平）作为多模式治疗的一部分，单次剂量为20mg/m²，每8小时一次，持续10天。通过临床观察以及包括心电图和超声心动图、四极胸壁血流图和肺动脉压力（PPA）间接测量在内的仪器检查，来控制单次给药或疗程给药的效果。对8例患者进行了PPA直接测量。在两个海拔高度，可立平均使患者的一般状况得到改善，运动后恢复时间缩短，PPA和二尖瓣反流容积减少，心脏泵功能疗效增加。可立平对前负荷和心肌收缩力没有明显影响。因此，该药物可推荐用于高地和低地CCF的多模式治疗。
